RecruitingPhase 1Phase 2NCT06715826

Target-specific immunoPET Imaging of Breast Cancer

Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer

Sponsor

RenJi Hospital

Enrollment

200 participants

Start Date

Sep 21, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Breast Cancer Metastatic Breast Neoplasms

Summary

The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET scan imaging using a specially designed antibody to help detect and visualize breast cancer more accurately. The goal is to develop a more targeted imaging approach than current standard scans. **You may be eligible if...** - You are a female aged 18–75 - You have a confirmed or suspected diagnosis of breast cancer - You are able to give informed consent **You may NOT be eligible if...** - You are pregnant - You have severe liver or kidney failure - You have had major surgery in the past month - You are allergic to antibody-based radiopharmaceuticals (the imaging agents) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]F-RESCA-RT4

Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RT4 injection.

DRUG[18F]F-RESCA-RB14

Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.